BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16387499)

  • 1. 6H,13H-Pyrazino[1,2-a;4,5-a']diindole analogs: probing the pharmacophore for allosteric ligands of muscarinic M2 receptors.
    Zlotos DP; Tränkle C; Abdelrahman A; Gündisch D; Radacki K; Braunschweig H; Mohr K
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1481-5. PubMed ID: 16387499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisquaternary caracurine V and iso-caracurine V salts as ligands for the muscle type of nicotinic acetylcholine receptors: SAR and QSAR studies.
    Zlotos DP; Gündisch D; Ferraro S; Tilotta MC; Stiefl N; Baumann K
    Bioorg Med Chem; 2004 Dec; 12(23):6277-85. PubMed ID: 15519170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing the pharmacophore for allosteric ligands of muscarinic M2 receptors: SAR and QSAR studies in a series of bisquaternary salts of caracurine V and related ring systems.
    Zlotos DP; Buller S; Stiefl N; Baumann K; Mohr K
    J Med Chem; 2004 Jul; 47(14):3561-71. PubMed ID: 15214783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
    Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
    Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
    Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
    Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
    Redka DS; Pisterzi LF; Wells JW
    Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding.
    Keller M; Tränkle C; She X; Pegoli A; Bernhardt G; Buschauer A; Read RW
    Bioorg Med Chem; 2015 Jul; 23(14):3970-90. PubMed ID: 25650309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, NMR conformational analysis and pharmacological evaluation of 7,7a,13,14-tetrahydro-6H-cyclobuta[b]pyrimido[1,2-a:3,4-a']diindole analogues as melatonin receptor ligands.
    Attia MI; Güclü D; Hertlein B; Julius J; Witt-Enderby PA; Zlotos DP
    Org Biomol Chem; 2007 Jul; 5(13):2129-37. PubMed ID: 17581657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding.
    Muth M; Bender W; Scharfenstein O; Holzgrabe U; Balatkova E; Tränkle C; Mohr K
    J Med Chem; 2003 Mar; 46(6):1031-40. PubMed ID: 12620079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors.
    Cembala TM; Forde SC; Appadu BL; Lambert DG
    Eur J Pharmacol; 2007 Aug; 569(1-2):37-40. PubMed ID: 17588565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of orthosteric and allosteric muscarinic M2 acetylcholine receptor ligands by affinity selection-mass spectrometry.
    Whitehurst CE; Nazef N; Annis DA; Hou Y; Murphy DM; Spacciapoli P; Yao Z; Ziebell MR; Cheng CC; Shipps GW; Felsch JS; Lau D; Nash HM
    J Biomol Screen; 2006 Mar; 11(2):194-207. PubMed ID: 16490772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric binding sites on muscarinic acetylcholine receptors.
    Wess J
    Mol Pharmacol; 2005 Dec; 68(6):1506-9. PubMed ID: 16183853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.
    Krogsgaard-Larsen N; Jensen AA; Kehler J
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5431-3. PubMed ID: 20719507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisquaternary ligands of the common allosteric site of M2 acetylcholine receptors: search for the minimum essential distances between the pharmacophoric elements.
    Nassif-Makki T; Tränkle C; Zlotos D; Bejeuhr G; Cambareri A; Pfletschinger C; Kostenis E; Mohr K; Holzgrabe U
    J Med Chem; 1999 Mar; 42(5):849-58. PubMed ID: 10072682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
    Elsinghorst PW; Cieslik JS; Mohr K; Tränkle C; Gütschow M
    J Med Chem; 2007 Nov; 50(23):5685-95. PubMed ID: 17944454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
    Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents.
    Muth M; Sennwitz M; Mohr K; Holzgrabe U
    J Med Chem; 2005 Mar; 48(6):2212-7. PubMed ID: 15771463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
    May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscarinic allosteric modulators: atypical structure-activity-relationships in bispyridinium-type compounds.
    Sürig U; Gaal K; Kostenis E; Tränkle C; Mohr K; Holzgrabe U
    Arch Pharm (Weinheim); 2006 Apr; 339(4):207-12. PubMed ID: 16572483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
    Lemaître S; Lepailleur A; Bureau R; Butt-Gueulle S; Lelong-Boulouard V; Duchatelle P; Boulouard M; Dumuis A; Daveu C; Lezoualc'h F; Pfeiffer B; Dauphin F; Rault S
    Bioorg Med Chem; 2009 Mar; 17(6):2607-22. PubMed ID: 19261477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.